Cartesian Therapeutics, Inc. (RNAC)
Market Closed
17 Apr, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary 
XBER $
10. 50
-0.07
-0.66%
$
294.01M Market Cap
- P/E Ratio
0% Div Yield
96,200 Volume
- Eps
$ 10.57
Previous Close Day Range
10.19 10.67
Year Range
8.85 41.87
Earnings results expected in 16 days
Summary
RNAC closed Thursday lower at $10.5, a decrease of 0.66% from Wednesday's close, completing a monthly decrease of -21.93% or $2.95. Over the past 12 months, RNAC stock lost -41.63%.
RNAC is not paying dividends to its shareholders.
The last earnings report, released on Mar 05, 2025, exceeded the consensus estimates by 0.23%. On average, the company has surpassed earnings expectations by 0.52%, based on the last three reports. The next scheduled earnings report is due on May 06, 2025.
Cartesian Therapeutics, Inc. has completed 1 stock splits, with the recent split occurring on Apr 05, 2024.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).
Want to track RNAC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
RNAC Chart
Cartesian Therapeutics, Inc. Dividends
RNAC is not paying dividends to its shareholders.
Cartesian Therapeutics, Inc. Earnings
| 6 May 2025 (16 Days) Date | | - Cons. EPS | - EPS |
| 5 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
| 8 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
RNAC is not paying dividends to its shareholders.
| 6 May 2025 (16 Days) Date | | - Cons. EPS | - EPS |
| 5 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
| 8 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
Cartesian Therapeutics, Inc. (RNAC) FAQ
What is the stock price today?
The current price is $10.50.
On which exchange is it traded?
Cartesian Therapeutics, Inc. is listed on NASDAQ (NMS).
What is its stock symbol?
The ticker symbol is RNAC.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 294.01M.
What is the earnings per share?
The EPS is -0.88.
When is the next earnings date?
The next earnings report will release on May 06, 2025.
Has Cartesian Therapeutics, Inc. ever had a stock split?
Cartesian Therapeutics, Inc. had 1 splits and the recent split was on Apr 05, 2024.
Cartesian Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Carsten Brunn Ph.D. CEO | NASDAQ (NMS) Exchange | US8162121045 ISIN |
| United States Country | 37 Employees | - Last Dividend | 5 Apr 2024 Last Split | - IPO Date |
Overview
Cartesian Therapeutics, Inc. is a trailblazing clinical-stage biotechnology firm dedicated to advancing the field of medicine through its innovative approach in mRNA cell therapies. With a focus on treating various autoimmune diseases, the company stands at the forefront of developing therapies that aim to revolutionize the way such conditions are treated. Cartesian Therapeutics is founded on a commitment to leveraging advanced science to create impactful solutions for patients struggling with autoimmune disorders. Headquartered in Gaithersburg, Maryland, the company embodies a spirit of innovation and a relentless pursuit of excellence in biotechnology.
Products and Services
Cartesian Therapeutics, Inc. has developed a robust pipeline of groundbreaking mRNA cell therapies designed to address a wide range of autoimmune diseases through innovative treatment modalities. Here's an overview of their leading products under development:
- Descartes-08: This cutting-edge product is an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy, which is currently in Phase 2b clinical development. It's specifically designed for treating generalized myasthenia gravis and is also being evaluated for its potential in treating patients with systemic lupus erythematosus. Furthermore, Descartes-08 is involved in myeloma autoimmune basket trials, exploring its utility in other autoimmune diseases.
- Descartes-15: Aimed at addressing both autoimmune diseases and myeloma, Descartes-15 represents another significant stride in Cartesian Therapeutics' pursuit of novel treatments. While specific details regarding its mechanism of action and development stage remain concise, Descartes-15 underscores the company's commitment to broadening its impact across multiple autoimmune conditions.
- Descartes-33: This product is currently in preclinical development and showcases Cartesian Therapeutics' ongoing efforts to extend its research and development into new therapeutic areas. Descartes-33 is focused on treating autoimmune diseases, indicating the company's continuous endeavor to innovate and expand its portfolio of solutions for autoimmune disorders.
Contact Information
Address: 704 Quince Orchard Road
Phone: 617 923 1400
2025 © Marketlog. All Rights Reserved.
